To add, or not to add an inhaled corticosteroid in moderate COPD: That is the question

Chest

Volumn 134, Issue 2, 2008, Pages 223-225

  Cazzola, Mario ^a   Matera, Maria Gabriella ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ADD ON THERAPY; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG INDICATION; EDITORIAL; HUMAN; INTERNET; PRACTICE GUIDELINE; PRIORITY JOURNAL; STEROID THERAPY;

EID: 49449112605     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.08-0855     Document Type: Editorial

References (14)

1. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532-555
3. GSK. Final variation assessment report: Seretide Diskus/ Viani Diskus Seretide Evohaler/Viani Evohaler (fluticasone propionate/salmeterol xinafoate). Available at: www.gsk.com/ media/pressreleases/2007/2007_07_09_GSK1092.htm. Accessed March 25, 2008
4. Rabe KF, Timmer W, Sagkriotis A, et al. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134:255-262
5. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31:416-469
6. Soriano JB, Sin DD, Zhang X, et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007; 131:682-689
7. Bateman ED, van Dyk M, Sagriotis A. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study. Pulm Pharmacol Ther 2008; 21:20-25
8. Singh D, Brooks J, Hagan G, et al. Superiority of triple therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63:592-598
9. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146:545-555
10. Hodder R, Kesten S, Menjoge S, et al. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Int J Chron Obstruct Pulm Dis 2007; 2:157-167
11. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125:249-259
12. 2-agonists and corticosteroids in stable COPD. Chest 2004; 126:220-237
13. Pistolesi M, Camiciottoli G, Paoletti M, et al. Identification of a predominant COPD phenotype in clinical practice. Respir Med 2008; 102:367-376
14. Cooper CB, Tashkin DP. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ 2005; 330:640-644